Business context and reporting period
The filing is Theravance, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2014. The supplied metadata names Innoviva, Inc., but the filing itself identifies Theravance, Inc. as the registrant. Theravance was a biopharmaceutical company with partnered respiratory products and an internally developed drug pipeline. It was pursuing a separation into two public companies; the statements do not reflect separation adjustments.
Financial performance and liquidity
Amounts below are in millions of dollars except per-share figures.
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Total net revenue | $0.2 | $1.3 |
| Research and development expense | $43.4 | $26.4 |
| Selling, general and administrative expense | $22.8 | $8.3 |
| Operating loss | $(66.2) | $(33.4) |
| Net loss | $(67.7) | $(37.4) |
| Basic and diluted net loss per share | $(0.62) | $(0.39) |
| Cash used in operating activities | $(50.6) | $(31.6) |
- Revenue included $0.9 million of VIBATIV sales, $0.7 million of GSK royalties, and $1.8 million of amortization of GSK-related intangible assets. Because amortization exceeded royalties, net royalty revenue was negative $1.1 million; total net revenue was only $0.2 million.
- Operating expenses totaled $66.4 million, versus $34.7 million a year earlier. R&D rose 64%, and SG&A rose 175%. Management cited employee and stock-compensation costs, clinical-trial spending, VIBATIV commercialization, and separation-related professional fees.
- No meaningful positive operating margin was reported; the company recorded a substantial operating loss relative to revenue.
- At March 31, cash and cash equivalents were $125.3 million, short-term investments $245.6 million, and marketable securities $59.8 million. Together, cash, cash equivalents, and marketable securities were approximately $430.8 million, excluding $0.8 million restricted cash. Total assets were $605.0 million, down from $681.3 million at year-end.
- Convertible subordinated notes were $287.5 million on the balance sheet. Their estimated fair value was $369.7 million. In April, a subsidiary issued $450 million of non-recourse 9% notes due 2029, with approximately $434.3 million net proceeds; the notes are supported by 40% of specified future GSK royalties. A $32 million reserve was set aside for potential GSK milestone payments.
- Q1 investing cash flow was positive $14.1 million, reflecting net investment-security maturities partly offset by $55 million of GSK milestone payments. Financing cash flow was positive $18.3 million, largely from stock issuance, including $12.9 million from GSK share purchases.
Material changes versus the prior comparable period
- Net loss increased by $30.3 million, principally as costs and expenses rose by $31.7 million.
- Operating cash use increased by $19.0 million. Stock-based compensation increased to $13.5 million from $6.1 million.
- Collaborative revenue fell 80%, partly because previously deferred GSK LABA collaboration revenue had been fully recognized in 2013. The company began recognizing VIBATIV revenue on a sell-through basis in Q1 2014.
- Interest expense declined 40% to $1.6 million, primarily because the 3% convertible notes due 2015 had converted into common shares in 2013.
Outlook, commentary, risks and unusual items
- Management said available cash and marketable securities were expected to fund anticipated operating needs for at least 12 months under current plans. It also anticipated funding Theravance Biopharma with approximately $400 million at separation, subject to plans, timing, and available cash.
- No quantified revenue or earnings guidance was provided. Management expected substantial R&D spending and continuing losses, and noted that advancing programs independently or commercializing VIBATIV without a partner could increase costs.
- The proposed separation faced execution, third-party consent, management-transition, and expense risks. The GSK master agreement would terminate if the separation was not completed by June 30, 2014. The filing also disclosed that the IRS declined to issue the requested tax ruling and indicated it viewed the distribution as taxable, creating potential tax liabilities for stockholders.
- GSK milestone payments under the LABA collaboration could total $220 million; $140 million had been paid by quarter-end, another $30 million was recorded in April, and $50 million of potential payments was estimated to be payable by year-end 2014.
- Commercialization risks included initially slow BREO/RELVAR uptake and payer coverage, competition, and reliance on GSK for partnered product commercialization. VIBATIV sales were limited, and its inventory value depended on materially increasing sales. The company also cited clinical-development, regulatory, manufacturing, partner, and financing risks.
- Subsequent to quarter-end, ANORO launched in the U.S.; the 9% royalty-backed notes were issued; and May changes to certain retention awards were expected to add $4.3 million of stock compensation and $5.0 million of cash-bonus expense over a one-year vesting period.
Important facts for investors to verify
- Confirm the registrant and corporate-name history, given the metadata’s Innoviva label and the filing’s Theravance, Inc. identification.
- Track GSK product sales, royalty receipts, amortization deductions, and the effect of the royalty-backed notes on cash available to the company.
- Verify completion terms, timing, funding allocation, and tax treatment of the proposed separation, including potential stockholder tax consequences.
- Assess whether VIBATIV sales can support its inventory carrying value and whether commercialization or supply constraints persist.
- Reconcile reported liquidity and monitor operating cash burn, milestone obligations, and financing needs against management’s stated 12-month liquidity expectation.